ABVC BioPharma Subsidiary Receives $230,000 Milestone Payment in Botanical Drug Partnership
BioLite, an ABVC BioPharma subsidiary, received a $230,000 milestone payment from AiBtl BioPharma, advancing their collaboration on botanical-derived treatments for depression and ADHD that could generate up to $667 million in total value.
BioLite, Inc., a subsidiary of ABVC BioPharma, has received a $230,000 milestone payment from AiBtl BioPharma as part of their strategic licensing agreement for botanical drug candidates ABV-1504 and ABV-1505. These compounds are being developed for Major Depressive Disorder and Attention-Deficit/Hyperactivity Disorder, representing significant opportunities in the growing mental health therapeutics market.
The payment marks continued progress in the partnership, with BioLite having received $230,000 cumulatively and remaining eligible for up to $7 million in future cash milestone payments. ABVC, as majority owner and co-licensor, has separately received $350,000 to date and could receive up to $6.65 million additional payments. On a consolidated basis, the ABVC group could benefit from up to $13.42 million in future cash payments if all milestones are achieved.
Beyond cash considerations, the agreement includes substantial equity components, with AiBtl issuing 46 million common shares split equally between ABVC and BioLite. When combining potential milestone payments, equity stakes, and future royalties, the total transaction could represent approximately $667 million in value based on internal valuations.
The collaboration addresses substantial market opportunities in central nervous system disorders. The anxiety and depression treatment market was valued at approximately $15.4 billion in 2024 and is projected to reach $19.3 billion by 2030. Similarly, the ADHD therapeutics market reached $14.3 billion in 2023 and is expected to grow to $18.6 billion by 2030.
The market potential is underscored by significant unmet medical needs globally. The World Health Organization reports that depression affects more than 380 million people worldwide and is a leading cause of disability. The Centers for Disease Control and Prevention identifies ADHD as one of the most common neurodevelopmental disorders in children, with a 9.8% prevalence rate among U.S. children.
Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the milestone payment underscores progress in the collaboration with AiBtl. While future payments remain contingent on milestone achievements, the combined structure of cash and equity provides both companies with an important foundation to advance development. The partnership aims to explore safe and effective botanical-based treatment options that may expand therapeutic choices for patients facing these major global health challenges.
The licensing partnership positions ABVC to potentially become a frontrunner in the emerging field of botanical CNS therapies. By combining potential cash inflows, equity stakes, and addressing a multi-billion-dollar market opportunity, ABVC believes it can strengthen its balance sheet and unlock transformational long-term value for shareholders while advancing innovative treatments for psychiatric disorders.